Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + metformin
- Development stage
- Unknown
- Lead developer
- Myopharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Celecoxib + metformin is a drug combination that has shown synergistic effects in inhibiting tumor growth, particularly in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The combination works by reducing the phosphorylation of mTOR and causing reactive oxygen species (ROS) aggregation in cancer cells, leading to DNA double-strand breaks and increased expression of the tumor suppressor factor p53. This combination has demonstrated superior efficacy compared to either drug alone in both in vitro and in vivo studies, showing enhanced inhibition of cell proliferation, migration, and increased induction of apoptosis. The combination therapy also appears to suppress Raf-MEK-ERK cascades and PI3K-AKT signaling, which may help overcome drug resistance.
- Brand names
- Celebrex
- Other names
- metformincelecoxibmetformin-Guangxi Medical University-hepatocellular carcinoma
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on celecoxib + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + metformin.